Literature DB >> 20824717

Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications.

Diana Bell1, Dianna Roberts, Merrill Kies, Pulivarthi Rao, Randal S Weber, Adel K El-Naggar.   

Abstract

BACKGROUND: Adenoid cystic carcinoma (ACC), a rare and progressive salivary malignancy, is characterized by cellular, morphologic, and clinical heterogeneity. The authors of this report hypothesized that the dual cellular composition of ACC plays an important role in biomarker evaluation, tumor biologic behavior, and response to therapy.
METHODS: To investigate the differential localization and expression of the c-Kit protein and the epidermal growth factor receptor (EGFR) protein, immunohistochemical analyses were performed on tissue arrays that were constructed from 199 tumors, and the results were correlated with clinicopathologic factors.
RESULTS: c-Kit expression was limited to the inner ductal epithelial cells, whereas EGFR expression was limited mainly to the outer myoepithelial cells in the majority of ACCs with tubular and cribriform patterns. In solid ACCs, c-Kit uniformly was positive, whereas EGFR consistently was negative. A significant statistical correlation was observed between c-Kit expression and a poor 3-year outcome, and EGFR expression was correlated with a better 3-year outcome.
CONCLUSIONS: The current findings underscored the importance of cellular subtype localization of biomarkers in the clinical and therapeutic stratification of patients with ACC.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824717      PMCID: PMC2998592          DOI: 10.1002/cncr.25541

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

Review 1.  Adenoid cystic carcinoma: a retrospective clinical review.

Authors:  A J Khan; M P DiGiovanna; D A Ross; C T Sasaki; D Carter; Y H Son; B G Haffty
Journal:  Int J Cancer       Date:  2001-06-20       Impact factor: 7.396

2.  [Long term results in adenoidcystic carcinoma].

Authors:  P R Issing; I Hemmanouil; L Wilkens; H Karstens; Th Lenarz
Journal:  Laryngorhinootologie       Date:  2002-02       Impact factor: 1.057

Review 3.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

Authors:  F Ciardiello; G Tortora
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

4.  Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma.

Authors:  Y M Jeng; C Y Lin; H C Hsu
Journal:  Cancer Lett       Date:  2000-06-01       Impact factor: 8.679

Review 5.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

Authors:  Michael C Heinrich; Charles D Blanke; Brian J Druker; Christopher L Corless
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

Review 6.  Epidermal growth factor receptor dependence in human tumors: more than just expression?

Authors:  Carlos L Arteaga
Journal:  Oncologist       Date:  2002

7.  Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.

Authors:  T Ettl; S Schwarz; N Kleinsasser; A Hartmann; T E Reichert; O Driemel
Journal:  Histopathology       Date:  2008-11       Impact factor: 5.087

8.  Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.

Authors:  Ricardo S Macarenco; Timothy S Uphoff; Heather Flynn Gilmer; Robert B Jenkins; Stephen N Thibodeau; Jean E Lewis; Julian R Molina; Ping Yang; Marie-Christine Aubry
Journal:  Mod Pathol       Date:  2008-06-27       Impact factor: 7.842

9.  Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin.

Authors:  Marilena Vered; Efraim Braunstein; Amos Buchner
Journal:  Head Neck       Date:  2002-07       Impact factor: 3.147

10.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

View more
  19 in total

1.  Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings.

Authors:  Yoshitsugu Mitani; Jie Li; Randal S Weber; Scott L Lippman; Elsa R Flores; Carlos Caulin; Adel K El-Naggar
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

2.  Salivary gland cancers: biology and molecular targets for therapy.

Authors:  Diana Bell; Ehab Y Hanna
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

3.  Cellular subtype may predict survival outcomes in salivary adenoid cystic carcinoma patients-a single-institution experience.

Authors:  Ehab Y Hanna; Ahmed S A Abdelmeguid; Dianna Roberts; Achim H Bell; Randal S Weber; Diana Bell
Journal:  Virchows Arch       Date:  2017-10-23       Impact factor: 4.064

4.  BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma.

Authors:  Gerson A Acasigua; Kristy A Warner; Felipe Nör; Joseph Helman; Alexander T Pearson; Anna C Fossati; Shaomeng Wang; Jacques E Nör
Journal:  Oral Oncol       Date:  2015-06-26       Impact factor: 5.337

5.  Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma.

Authors:  Diana Bell; Dianna Roberts; Matthew Karpowicz; Ehab Y Hanna; Randal S Weber; Adel K El-Naggar
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

6.  Development and characterization of salivary adenoid cystic carcinoma cell line.

Authors:  Jie Li; Laszlo Perlaky; Pulivarthi Rao; Randal S Weber; Adel K El-Naggar
Journal:  Oral Oncol       Date:  2014-07-30       Impact factor: 5.337

Review 7.  Molecular Pathology and Biomarkers.

Authors:  Patrick K Ha; Göran Stenman
Journal:  Adv Otorhinolaryngol       Date:  2016-04-12

8.  Adenoid cystic carcinoma of head and neck: apropos of a case.

Authors:  Susana Alexandra Rodrigues Graça; Hugo Sequeira; Gustavo Coelho; Horácio Costa
Journal:  BMJ Case Rep       Date:  2012-08-21

9.  Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations.

Authors:  Tatiana V Karpinets; Yoshitsugu Mitani; Bin Liu; Jianhua Zhang; Kristen B Pytynia; Linton D Sellen; Danice T Karagiannis; Renata Ferrarotto; Andrew P Futreal; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2021-05-19       Impact factor: 12.531

10.  Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.

Authors:  Renata Ferrarotto; Yoshitsugu Mitani; Daniel J McGrail; Kaiyi Li; Tatiana V Karpinets; Diana Bell; Steven J Frank; Xingzhi Song; Michael E Kupferman; Bin Liu; J Jack Lee; Bonnie S Glisson; Jianhua Zhang; Jon C Aster; Shiaw-Yih Lin; P Andrew Futreal; John V Heymach; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2020-11-10       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.